Andreas Brückner

Novartis Pharma AG, Switzerland

Poster(s):

• (B-018) Estimating the incidence and prevalencehe incidence of second primary malignancy in men diagnosed with prostate cancer in the US during 2000-2022, as recorded in the US SEER 17 Registries
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET